Paul Pollack

Learn More
BACKGROUND & AIMS This study evaluated the efficacy and safety of adalimumab, a fully human, anti-tumor necrosis factor monoclonal antibody administered subcutaneously, in the maintenance of response and remission in patients with moderate to severe Crohn's disease (CD). METHODS Patients received open-label induction therapy with adalimumab 80 mg (week 0)(More)
BACKGROUND & AIMS Tumor necrosis factor blockade has been shown to be an effective treatment strategy in Crohn's disease (CD). Adalimumab is a human immunoglobulin G1 (IgG(1)) monoclonal antibody targeting tumor necrosis factor (TNF). A randomized, double-blind, placebo-controlled, dose-ranging trial was performed to evaluate the efficacy of adalimumab(More)
BACKGROUND Adalimumab induced clinical remission after four weeks in patients with active Crohn's disease in the CLASSIC I trial. OBJECTIVE To evaluate long term efficacy and safety of adalimumab maintenance therapy in Crohn's disease in a follow-on randomised controlled trial (CLASSIC II). METHODS In the preceding CLASSIC I trial, 299 patients with(More)
BACKGROUND & AIMS We investigated the efficacy of adalimumab for inducing and maintaining mucosal healing in patients with Crohn's disease (CD). METHODS A randomized, double-blind, placebo-controlled trial (extend the safety and efficacy of adalimumab through endoscopic healing [EXTEND]) evaluated adalimumab for induction and maintenance of mucosal(More)
BACKGROUND Adalimumab, a fully human tumor necrosis factor (TNF) antagonist, is an effective treatment for patients with Crohn disease who are naive to the chimeric TNF antagonist, infliximab. No anti-TNF agent has been evaluated prospectively in patients with Crohn disease who had responded to another anti-TNF agent and then lost that response or were(More)
OBJECTIVE To evaluate the efficacy of adalimumab in the healing of draining fistulas in patients with active Crohn's disease (CD). DESIGN A phase III, multicentre, randomised, double-blind, placebo controlled study with an open-label extension was conducted in 92 sites. PATIENTS A subgroup of adults with moderate to severely active CD (CD activity index(More)
We study the distribution of solutions n to the congruence σ(n) ≡ a (mod n). After excluding obvious families of solutions, we show that the number of these n ≤ x is at most x, as x → ∞, uniformly for integers a with |a| ≤ x. As a concrete example, the number of composite solutions n ≤ x to the congruence σ(n) ≡ 1 (mod n) is at most x. These results are(More)
The inpatient and outpatient records were reviewed for 527 patients, including 138 children, who were discharged on home total parenteral nutrition and followed by the University of California, Los Angeles, home total parenteral nutrition service for a minimum of 1 week between April 1973 and October 1991. The total follow-up time was 1154 patient years;(More)
OBJECTIVES We evaluated the effects of adalimumab maintenance therapy on health-related quality of life (HRQOL) in patients with moderate to severe Crohn's disease. METHODS In a Phase III, randomized, double-blind clinical trial (CHARM) of moderate to severe Crohn's disease patients, HRQOL outcomes were compared between the adalimumab maintenance(More)
Suppose g ≥ 2. A natural number N is called a repdigit in base g if it has the shape a g −1 g−1 for some 1 ≤ a < g, i.e., if all of its digits in its base g expansion are equal. The number N is called perfect if σ(N) = 2N , where σ(N) := � d|N d is the usual sum of divisors function. We show that in each base g, there are at most finitely many repdigit(More)